Rationale and study design for a multicenter, randomized, double-blind, placebo-controlled study of the effects of tolvaptan on the acute and chronic outcomes of patients hospitalized with worsening congestive heart failure

被引：36

作者：

Gheorghiade, M

Gattis, WA

Barbagelata, A

Adams, KF

Elkayam, U

Orlandi, C

O'Connor, CM

机构：

[1] Northwestern Univ, Feinberg Sch Med, Div Cardiol, Chicago, IL 60611 USA

[2] Duke Clin Res Inst, Durham, NC USA

[3] Inst Cardiol & Cirugia, Buenos Aires, DF, Argentina

[4] Univ N Carolina, Chapel Hill, NC USA

[5] Univ So Calif, Los Angeles, CA USA

[6] Otsuka Maryland Res Inst, Baltimore, MD USA

来源：

AMERICAN HEART JOURNAL | 2003年 / 145卷 / 02期

关键词：

D O I：

10.1067/mhj.2003.154

中图分类号：

R5 [内科学];

学科分类号：

1002 [临床医学]; 100201 [内科学];

摘要：

引用

页码：S51 / S54

页数：4

共 10 条

[1]

*AM HEART ASS, 2002, 2002 HEART STROK STA

[2]

Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction [J].

Cooper, HA ;

Dries, DL ;

Davis, CE ;

Shen, YL ;

Domanski, MJ .

CIRCULATION, 1999, 100 (12) :1311-1315

[3]

Short-term intravenous milrinone for acute exacerbation of chronic heart failure - A randomized controlled trial [J].

Cuffe, MS ;

Califf, RM ;

Adams, KF ;

Benza, R ;

Bourge, R ;

Colucci, WS ;

Massie, BM ;

O'Connor, CM ;

Pina, I ;

Quigg, R ;

Silver, MA ;

Georghiade, M .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 287 (12) :1541-1547

[4]

Rationale and design of the OPTIME CHF trial: Outcomes of a prospective trial of intravenous milrinone for exacerbations of chronic heart failure [J].

Cuffe, MS ;

Califf, RM ;

Adams, KF ;

Bourge, RC ;

Colucci, W ;

Massie, B ;

O'Connor, CM ;

Pina, I ;

Quigg, R ;

Silver, M ;

Robinson, LA ;

Leimberger, JD ;

Gheorghiade, M .

AMERICAN HEART JOURNAL, 2000, 139 (01) :15-22

[5]

COMPARISON OF NEUROENDOCRINE ACTIVATION IN PATIENTS WITH LEFT-VENTRICULAR DYSFUNCTION WITH AND WITHOUT CONGESTIVE-HEART-FAILURE - A SUBSTUDY OF THE STUDIES OF LEFT-VENTRICULAR DYSFUNCTION (SOLVD) [J].

FRANCIS, GS ;

BENEDICT, C ;

JOHNSTONE, DE ;

KIRLIN, PC ;

NICKLAS, J ;

LIANG, CS ;

KUBO, SH ;

RUDINTORETSKY, E ;

YUSUF, S .

CIRCULATION, 1990, 82 (05) :1724-1729

[6]

Vasopressin receptor blockade with tolvaptan in chronic heart failure: Differential effects in normonatremic and hyponatremic patients [J].

Gheorghiade, M ;

Konstam, MA ;

Udelson, JE ;

Ouyang, J ;

Orlandi, C .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2002, 39 (05) :171A-171A

[7]

Gheorghiade M, 2000, CIRCULATION, V102, P592

[8]

Vasopressin: A therapeutic target in congestive heart failure? [J].

Goldsmith, SR .

JOURNAL OF CARDIAC FAILURE, 1999, 5 (04) :347-356

[9]

Mechanisms of disease - Hormones and hemodynamics in heart failure [J].

Schrier, RW ;

Abraham, WT .

NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (08) :577-585

[10]

Acute hemodynamic effects of conivaptan, a dual V1A and V2 vasopressin receptor antagonist, in patients with advanced heart failure [J].

Udelson, JE ;

Smith, WB ;

Hendrix, GH ;

Painchaud, CA ;

Ghazzi, M ;

Thomas, I ;

Ghali, JK ;

Selaru, P ;

Chanoine, F ;

Pressler, ML ;

Konstam, MA .

CIRCULATION, 2001, 104 (20) :2417-2423

← 1 →